Laura Salyers, MD
Psychiatry · Missoula, MTNPI 1801835491
Payments from drug & device makers
What this record shows
Johnson & Johnson accounts for 61.9% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2023 at $2,266 and has fallen 83.3% since, to $379 in 2025. Among psychiatry clinicians in MT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 61 payments — averaging $57.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$2K
- Amgen$450
- Neurocrine Biosciences, Inc.$268
- Teva Pharmaceuticals USA, Inc.$123
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$108
- Vanda Pharmaceuticals Inc.$97
- plus $299 from 7 others
What the payments were for
- Travel & lodging$1,82752%
- Food & beverage$1,70148%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 13 | $2,183 |
| Amgen | 9 | $450 |
| Neurocrine Biosciences, Inc. | 13 | $268 |
| Teva Pharmaceuticals USA, Inc. | 5 | $123 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $108 |
| Vanda Pharmaceuticals Inc. | 3 | $97 |
| Alkermes, Inc. | 1 | $74 |
| Indivior Inc. | 4 | $69 |
| AbbVie | 2 | $43 |
| Lundbeck LLC | 2 | $42 |
| Janssen Scientific Affairs, LLC | 1 | $30 |
| Otsuka America Pharmaceutical, Inc. | 1 | $24 |
| Sunovion Pharmaceuticals Inc. | 2 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,528 in reported general payments places this provider in the 90th percentile of 82 psychiatry providers in Montana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 16 | $82,976 |
| AustedoDeutetrabenazine | 13 | $67,756 |
| CaplytaLumateperone Tosylate | 24 | $38,294 |
| Invega SustennaPaliperidone Palmitate | 11 | $36,196 |
| RexultiBrexpiprazole | 16 | $23,271 |
| VraylarCariprazine Hcl | 14 | $19,544 |
| TrintellixVortioxetine Hydrobromide | 14 | $10,975 |
| VyvanseLisdexamfetamine Dimesylate | 13 | $9,190 |
| BelsomraSuvorexant | 17 | $7,405 |
| Lurasidone Hcl | 38 | $4,600 |
| Bupropion XlBupropion Hcl | 167 | $3,185 |
| Clomipramine Hcl | 28 | $2,596 |
| Lamotrigine | 262 | $2,393 |
| Olanzapine | 81 | $2,293 |
| Quetiapine Fumarate | 171 | $1,906 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo, Loxapine | $123 | $151,42244 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $108 | $38,29424 claims |
| Johnson & JohnsonInvega Sustenna | $2,183 | $36,19611 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $24 | $23,27116 claims |
| AbbVieVraylar | $43 | $19,54414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 82 psychiatry providers in Montana.
Other psychiatry in Missoula
- Michael TheinMissoula$4K
- Christopher HelleksonMissoula$693
- Kary AytesMissoula$237
- Phillip HolmanMissoula$155
- Patrick MaidmanMissoula$118
- Robert MunjalMissoula$109
- Jason MolinaroMissoula$71
- Nicholas FreudenbergMissoula$48
- Troy StilesBillings$221K
- Erin AmatoBillings$88K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.